Leukemia, Myelodysplasia, Transplantation
News
FDA grants "breakthrough" status to investigational T-cell therapy for relapsed/refractory ALL
News
FDA grants "breakthrough" status to investigational T-cell therapy for relapsed/refractory ALL
Conference Coverage
Study validates drug’s efficacy in CLL/SLL
Ibrutinib conferred these benefits irrespective of baseline clinical characteristics or molecular features, including 17p deletion. Atrial...
Conference Coverage
Phase 2 results lead to breakthrough designation
The decision was based on promising results of a phase 2 trial, which were presented at the 50th Annual Meeting of the American Society of...
Conference Coverage
QOL data support ATRA-ATO in APL
Previously released data from a phase 3 study showed that ATRA-ATO can improve survival rates in APL patients when compared to ATRA plus...
News
Enhancing gene delivery to HSCs
Credit: Chad McNeeley Scientists say they’ve overcome a major hurdle to developing gene therapies for blood disorders. They found the drug...
News
Ofatumumab falls short in CLL, DLBCL
Credit: Linda Bartlett The anti-CD20 antibody ofatumumab (Arzerra) has failed to meet the primary endpoint in two phase 3 trials, according to...
News
Elderly AML patients respond to first-line azacitidine
Key clinical point: Elderly patients with newly diagnosed AML benefit from first-line azacitidine.Major finding: Median overall survival was 10.4...
News
Group finds master regulator of MYC
Credit: Juha Klefstrom New research indicates that an unexpected partnership between the MYC oncogene and a non-coding RNA called PVT1 could be...
Feature
Targeting B-cell signaling pathways: a central role for Bruton’s tyrosine kinase
News
Long-term complications after ALL minimal, study shows
Credit: Bill Branson Children recently diagnosed with standard-risk acute lymphoblastic leukemia (ALL) are likely to have few long-term...